– Groove, an automation-driven sales engagement platform, announced that it closed a $45 million series B round led by Viking Global Investors with participation from Capital One Ventures, Level Equity, Quest Venture Partners, and Uncork Capital.
– The funds bring the company’s total raised to over $57 million to date, which cofounder and CEO Chris Rothstein says will be put toward product development and international workforce growth.
– It’s Groove’s assertion that the pandemic-fueled shift to digital selling is driving the convergence of sales engagement and revenue operations.
– But digital selling has also exposed a weakness in some companies’ customer relationship management (CRM) software: a lack of adoption.

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
– Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

– Arctic Wolf has raised $150m in a Series C funding round.
– The round was led by Viking Global Investors and Owl Rock, a division of Blue Owl Capital.
– The company has achieved a valuation of $4.3bn.
– Capitalizing on hypergrowth and strong demand for its technology and services, Arctic Wolf is cementing its position as the market leader in Security Operations.
– With its innovative approach to solving cybersecurity’s effectiveness problem, Arctic Wolf is setting a new standard for customers looking to end cyber risk by leveraging the cloud-native Arctic Wolf® Platform and the Concierge Security® Team.
– With this significantly oversubscribed round, Arctic Wolf will continue accelerating its market momentum, expand operations globally and bring to market new products and innovation to build world-class Security Operations for customers around the globe.

– Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding.
– The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire.
– The company intends to use the funds to expand its pipeline and scale production in global markets.

– Iterable, a San Francisco, CA-based provider of a martech platform focusing on the development and optimization of cross-channel experiences, raised $200m in Series E funding.
– The round was led by new investors Silver Lake, Adams Street Partners, Glynn Capital, and DTCP and existing investors CRV, Viking Global Investors, Blue Cloud Ventures, and Capital Ventures.
– The new investment will be used to continue to develop the platform and expand its business reach.

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

– Lightmatter is a leader in photonic computing.
– The company raised $80m in Series B funding.
– Viking Global Investors led the round with participation from GV (formerly Google Ventures), Hewlett Packard Enterprise (HPE), Lockheed Martin, Matrix Partners, SIP Global Partners, Spark Capital, and several others.

– Nuvalent is a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer.
– The company raised $135m in Series B funding.
– Bain Capital Life Sciences led the round and was joined by Deerfield Management, Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital.

– Icosavax closed a $100m Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company).
– A previously announced funding from Open Philanthropy was included in this round.
– The proceeds of the financing will support the development of Icosavax’s bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of the company’s pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.

– Ecovative is a Green Island, NY-based mycelium technology company.
– The company raised $60m in Series D funding.
– The round was led by Viking Global Investors, with participation from Senator Investment Group, AiiM Partners, Trousdale Ventures and other investors.
– Steve Sherwood, Chairman of CWS Capital Partners, will be joining the company’s board.

– ID.me, a leading digital identity network that allows consumers to prove who they are online while controlling how their information is shared with brands, has raised $100m in a Series C funding round led by Viking Global Investors.
– Counterpoint Global (Morgan Stanley), PSP Growth, Lead Edge Capital, CapitalG, WndrCo, Willoughby Capital, BoxGroup and Moonshots Capital joined the round.
– Prominent investors include Marcelo Claure, Alexa Von Tobel and Dan Rosensweig.

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.

– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.

– Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating therapies for children and adults with cancer, announced a $130 million Series B financing.
– The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

– Day One Biopharmaceuticals announced a $130m Series B financing round bringing total investment in the company to $190m.
– The round was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors.
– Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.
– Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the Company’s lead program, DAY101.